Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndromePopulation Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease.The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients.Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.Initiating and Managing Patients with Venous Thromboembolism on Anticoagulant Drugs: A Practical Overview.Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.Filtering Out Use of DOACs in Hemodialysis.Direct oral anticoagulant considerations in solid organ transplantation: A review.The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation.Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis.The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.Defibrillation Testing During ICD Implantation - Should we or Should we Not?Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.Pipe Dreams About Apixaban for Stroke Prevention in Renal Impairment.
P2860
Q26766303-129A24A2-4911-4604-8389-40DF25DF7532Q28067420-0B90419E-BFBD-4FCE-8FD5-E123D5D806B1Q33729811-5F81C2D5-B3FD-4ADF-ADC9-2D82B2FD88A0Q38665579-DCA565A8-C4F2-4FA6-AB61-8034C4E12ED5Q38735704-1237EA88-5FBC-4EC3-AC55-7C9D6272A260Q38800081-591A336D-14DA-4052-B2CB-8F9194BE69ABQ38926117-5F3AEAEB-82DC-4AD2-9BE8-447B9BC3DE5FQ39002055-C14AFBAD-7832-4560-AC59-E160BC5FAD5AQ39003917-0C8F8C7C-9FD0-4C71-9682-25145DE84CA4Q39012313-54AA7AF1-C8B9-40FA-B821-F538A8EB64A0Q42265888-C1725DE3-84FC-44B3-8DA7-E3714E323C11Q46304498-E9522277-070D-4BA7-A333-3427729C1557Q47118947-23CEEED8-EA63-4396-A48D-02984A62A3FDQ47148139-46F43544-F6E6-4586-BA8C-816AA52603B3Q47789803-FD5312E6-7413-4F47-A9AD-B5B0E048C876Q48952027-7ECAFCF0-A422-4BEC-BDEC-7B035224A497Q49850586-10F1BBFF-09E1-4792-A523-48CBC7B5AFAFQ50794115-3AF0A501-7FA9-466B-BCB7-1DC317BF1FA8Q53622758-928D5CAF-F6B7-4E1B-A2B6-27A50CD6D6C4Q53724995-BE545573-6EC5-4A2C-A67F-944A94F693E9
P2860
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Effect of renal impairment on ...... amics, and safety of apixaban.
@en
Effect of renal impairment on ...... amics, and safety of apixaban.
@nl
type
label
Effect of renal impairment on ...... amics, and safety of apixaban.
@en
Effect of renal impairment on ...... amics, and safety of apixaban.
@nl
prefLabel
Effect of renal impairment on ...... amics, and safety of apixaban.
@en
Effect of renal impairment on ...... amics, and safety of apixaban.
@nl
P2093
P2860
P356
P1476
Effect of renal impairment on ...... amics, and safety of apixaban.
@en
P2093
Andrew Shenker
Charles E Frost
Frank LaCreta
Janice Pursley
Jessie Wang
Ming Chang
Rebecca A Boyd
Wonkyung Byon
Zhigang Yu
P2860
P304
P356
10.1002/JCPH.633
P577
2015-09-11T00:00:00Z